Recruitment successfully closes early for a diagnostic Phase II trial in neuroendocrine tumours
Sydney, Australia 19 December 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the early recruitment closure for its Phase II diagnostic 64Cu-SARTATE trial, DISCO (NCT04438304)1, for patients with known or…